CAMP Stock — CAMP4 Therapeutics Corporation: Cash, EV, Pipeline

Share price

$4.24

Market cap

$266.1M

Cash

$86.4M

Enterprise value

$179.7M

Balance sheet

Cash	$86.4M
Debt	$0.0M
Net cash	$86.4M
Enterprise value	$179.7M
Basic shares	51.9M shares
Fully diluted shares	75.6M shares
Fully diluted market cap	$320.6M
Cash per share	$1.66

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CAMP daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	CMP-CPS-001	Phase 1	Healthy Volunteers; OTC Deficiency	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

CMP-002

Phase 2 · Active Modality: ASO

Target SYNGAP1

Indications

SYNGAP1-related disorder (Phase 2)

Status note Lead product candidate; intrathecally delivered ASO. Cleared to initiate Phase 1/2 clinical trial by Australia's TGA (July 2026) and Argentina's ANMAT; U.S. trial subject to FDA IND acceptance. Company also holds RAP Platform collaborations with Fulcrum, BioMarin, and GSK, none tied to CMP-002 in the excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	CMP-CPS-001
Lead indication	Healthy Volunteers
Lead phase	Phase 1
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06247670	Phase 1	Active, not recruiting	Sponsor	CAMP	—	Healthy Volunteers; OTC Deficiency	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for CAMP4 Therapeutics Corporation on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

CAMP — CAMP4 Therapeutics Corporation